East Rutherford, NJ – November 20, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced it has entered into a definitive agreement to acquire Avista Pharma Solutions (Avista), a contract development, manufacturing, and testing organization, for approximately $252 million.  Avista is a portfolio company of Ampersand Capital Partners, a leading healthcare focused private equity firm.  With this acquisition, Cambrex will enter the large […]